Adverse events occurring in ≥2 patients in placebo or PF-00547,659 combined groups (single- and multiple-dose study phases combined)
| System organ class/preferred term | Percentage of patients with all-cause (treatment-related) adverse events | |
| Placebo (N=20) | PF-00547,659 (N=60) | |
| Any adverse event | 75 (20) | 82 (37) |
| Severe adverse events | 10 (0) | 13 (5) |
| Headache | 10 (5) | 30 (13) |
| Abdominal pain* | 25 (0) | 20 (0) |
| Worsening of ulcerative colitis | 15 (0) | 13 (0) |
| Fatigue | 10 (10) | 13 (5) |
| Arthralgia | 10 (0) | 10 (3) |
| Influenza/influenza-like illness | 0 (0) | 10 (2) |
| Gastroenteritis/enteritis | 5 (0) | 8 (0) |
| Anaemia† | 0 (0) | 8 (2) |
| Nasopharyngitis | 10 (0) | 7 (2) |
| Respiratory tract infection‡ | 0 (0) | 7 (2) |
| Nausea | 10 (0) | 5 (3) |
| Dizziness | 5 (0) | 5 (3) |
| Peripheral oedema | 0 (0) | 5 (2) |
| Back pain | 15 (0) | 3 (0) |
| Vomiting | 5 (0) | 3 (0) |
| Erythema | 5 (5) | 3 (0) |
| Insomnia (initial) | 0 (0) | 3 (3) |
| Eczema | 0 (0) | 3 (3) |
| Pruritis | 0 (0) | 3 (3) |
| Hot flush | 0 (0) | 3 (3) |
| Pain (not otherwise specified) | 0 (0) | 3 (0) |